Clinical and epidemiological features of Chryseobacterium indologenes infections: Analysisof 215 cases

Fu Lun Chen, Giueng Chueng Wang, Sing On Teng, Tsong Yih Ou, Fang Lan Yu, Wen Sen Lee

研究成果: 雜誌貢獻文章

61 引文 (Scopus)

摘要

Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium indologenes infections and antimicrobial susceptibilities of C indologenes. Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at a medical center, we analyzed the relationship between the prevalence of C indologenes infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic susceptibility, and outcomes. Results: Colistin and tigecycline were introduced into clinical use at this medical center since August 2006. The increasing numbers of patients with C indologenes pneumonia and bacteremia correlated to increased consumption of colistin ( p=0.018) or tigecycline ( p=0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate was 63.6% and 35.2% ( p=0.015), respectively. Administration of appropriate antibiotics showed significant benefit in 14-day survival in patients with C indologenes bloodstream infection ( p=0.040). In bacteremic patients, old cardiovascular accident ( p=0.036) and cancer ( p=0.014) were the most common comorbidity. The most common co-infection pathogen in patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6%), followed by Pseudomonas aeruginosa (23/91, 25.3%), carbapenem-resistant A baumannii (22/91, 24.2%), and Klebseilla pneumoniae (13/91, 14.3%). Antimicrobial susceptibility testing of the 215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%). Conclusion: The present study showed a trend of increasing prevalence of C indologenes infection after introduction of colistin and tigecycline usage. The bacteremia group had higher mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam, ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis. Trimethoprim-sulfamethoxazole was a potential antimicrobial agent invitro for C indologenes. To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.
原文英語
頁(從 - 到)425-432
頁數8
期刊Journal of Microbiology, Immunology and Infection
46
發行號6
DOIs
出版狀態已發佈 - 十二月 2013

指紋

Chryseobacterium
Colistin
Pneumonia
Bacteremia
Infection
Sulfamethoxazole Drug Combination Trimethoprim
Anti-Bacterial Agents
Cefoperazone
Sulbactam
Acinetobacter baumannii
Carbapenems
Ceftazidime
Mortality
Fluoroquinolones
Hospital Mortality
Anti-Infective Agents
Coinfection
Pseudomonas aeruginosa
Accidents
Prescriptions

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Immunology and Microbiology(all)
  • Infectious Diseases

引用此文

Clinical and epidemiological features of Chryseobacterium indologenes infections : Analysisof 215 cases. / Chen, Fu Lun; Wang, Giueng Chueng; Teng, Sing On; Ou, Tsong Yih; Yu, Fang Lan; Lee, Wen Sen.

於: Journal of Microbiology, Immunology and Infection, 卷 46, 編號 6, 12.2013, p. 425-432.

研究成果: 雜誌貢獻文章

@article{4945f414f78a4f8c8856ec17090c1854,
title = "Clinical and epidemiological features of Chryseobacterium indologenes infections: Analysisof 215 cases",
abstract = "Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium indologenes infections and antimicrobial susceptibilities of C indologenes. Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at a medical center, we analyzed the relationship between the prevalence of C indologenes infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic susceptibility, and outcomes. Results: Colistin and tigecycline were introduced into clinical use at this medical center since August 2006. The increasing numbers of patients with C indologenes pneumonia and bacteremia correlated to increased consumption of colistin ( p=0.018) or tigecycline ( p=0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate was 63.6{\%} and 35.2{\%} ( p=0.015), respectively. Administration of appropriate antibiotics showed significant benefit in 14-day survival in patients with C indologenes bloodstream infection ( p=0.040). In bacteremic patients, old cardiovascular accident ( p=0.036) and cancer ( p=0.014) were the most common comorbidity. The most common co-infection pathogen in patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6{\%}), followed by Pseudomonas aeruginosa (23/91, 25.3{\%}), carbapenem-resistant A baumannii (22/91, 24.2{\%}), and Klebseilla pneumoniae (13/91, 14.3{\%}). Antimicrobial susceptibility testing of the 215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4{\%}), followed by cefoperazone-sulbactam (48.0{\%}). Conclusion: The present study showed a trend of increasing prevalence of C indologenes infection after introduction of colistin and tigecycline usage. The bacteremia group had higher mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam, ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis. Trimethoprim-sulfamethoxazole was a potential antimicrobial agent invitro for C indologenes. To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.",
keywords = "Chryseobacterium indologenes, Colistin, Tigecycline, Trimethoprim-sulfamethoxazole",
author = "Chen, {Fu Lun} and Wang, {Giueng Chueng} and Teng, {Sing On} and Ou, {Tsong Yih} and Yu, {Fang Lan} and Lee, {Wen Sen}",
year = "2013",
month = "12",
doi = "10.1016/j.jmii.2012.08.007",
language = "English",
volume = "46",
pages = "425--432",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "0253-2662",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - Clinical and epidemiological features of Chryseobacterium indologenes infections

T2 - Analysisof 215 cases

AU - Chen, Fu Lun

AU - Wang, Giueng Chueng

AU - Teng, Sing On

AU - Ou, Tsong Yih

AU - Yu, Fang Lan

AU - Lee, Wen Sen

PY - 2013/12

Y1 - 2013/12

N2 - Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium indologenes infections and antimicrobial susceptibilities of C indologenes. Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at a medical center, we analyzed the relationship between the prevalence of C indologenes infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic susceptibility, and outcomes. Results: Colistin and tigecycline were introduced into clinical use at this medical center since August 2006. The increasing numbers of patients with C indologenes pneumonia and bacteremia correlated to increased consumption of colistin ( p=0.018) or tigecycline ( p=0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate was 63.6% and 35.2% ( p=0.015), respectively. Administration of appropriate antibiotics showed significant benefit in 14-day survival in patients with C indologenes bloodstream infection ( p=0.040). In bacteremic patients, old cardiovascular accident ( p=0.036) and cancer ( p=0.014) were the most common comorbidity. The most common co-infection pathogen in patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6%), followed by Pseudomonas aeruginosa (23/91, 25.3%), carbapenem-resistant A baumannii (22/91, 24.2%), and Klebseilla pneumoniae (13/91, 14.3%). Antimicrobial susceptibility testing of the 215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%). Conclusion: The present study showed a trend of increasing prevalence of C indologenes infection after introduction of colistin and tigecycline usage. The bacteremia group had higher mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam, ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis. Trimethoprim-sulfamethoxazole was a potential antimicrobial agent invitro for C indologenes. To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.

AB - Purpose: This study investigates the clinical and epidemiological features of Chryseobacterium indologenes infections and antimicrobial susceptibilities of C indologenes. Methods: With 215 C indologenes isolates between January 1, 2004 and September 30, 2011, at a medical center, we analyzed the relationship between the prevalence of C indologenes infections and total prescription of colistin and tigecycline, clinical manifestation, antibiotic susceptibility, and outcomes. Results: Colistin and tigecycline were introduced into clinical use at this medical center since August 2006. The increasing numbers of patients with C indologenes pneumonia and bacteremia correlated to increased consumption of colistin ( p=0.018) or tigecycline ( p=0.049). Among patients with bacteremia and pneumonia, the in-hospital mortality rate was 63.6% and 35.2% ( p=0.015), respectively. Administration of appropriate antibiotics showed significant benefit in 14-day survival in patients with C indologenes bloodstream infection ( p=0.040). In bacteremic patients, old cardiovascular accident ( p=0.036) and cancer ( p=0.014) were the most common comorbidity. The most common co-infection pathogen in patients with C indologenes pneumonia was Acinetobacter baumannii (36/91, 39.6%), followed by Pseudomonas aeruginosa (23/91, 25.3%), carbapenem-resistant A baumannii (22/91, 24.2%), and Klebseilla pneumoniae (13/91, 14.3%). Antimicrobial susceptibility testing of the 215 isolates showed that trimethoprim-sulfamethoxazole was the most active agent (susceptibility rate: 87.4%), followed by cefoperazone-sulbactam (48.0%). Conclusion: The present study showed a trend of increasing prevalence of C indologenes infection after introduction of colistin and tigecycline usage. The bacteremia group had higher mortality rate than the pneumonia group. Increasing resistance to piperacillin-tazobactam, ceftazidime, cefepime, and newer fluoroquinolone were noticed in our analysis. Trimethoprim-sulfamethoxazole was a potential antimicrobial agent invitro for C indologenes. To avoid collateral damage, we emphasize the importance of antibiotic stewardship program.

KW - Chryseobacterium indologenes

KW - Colistin

KW - Tigecycline

KW - Trimethoprim-sulfamethoxazole

UR - http://www.scopus.com/inward/record.url?scp=84889663753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889663753&partnerID=8YFLogxK

U2 - 10.1016/j.jmii.2012.08.007

DO - 10.1016/j.jmii.2012.08.007

M3 - Article

C2 - 23022462

AN - SCOPUS:84889663753

VL - 46

SP - 425

EP - 432

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 0253-2662

IS - 6

ER -